News

Edition 12 ALLG News celebrates a groundbreaking milestone in blood cancer research that is set to change 40 years of standard practice. The global recognition of ALLG’s BM12 CAST trial, led by Professor David Curtis and presented at the European Hematology Association Congress 2025 and published in the New England Journal of Medicine, has delivered one of the most significant advances in transplant medicine in 40 years. The results of this trial showed that a simplified, less toxic treatment regimen can triple survival rates for patients undergoing blood stem cell transplants while reducing life-threatening complications.

The BM12 CAST trial is already adopted in eight Australasian hospitals and is being recognised around the world for its potential to become the new global standard for Graft Versus Host Disease (GVHD) prevention in matched sibling donor transplants. In this edition, we recognise the ongoing commitment and drive of our members in pursuing research that changes clinical practice and improves lives.

Download Edition 12

ALLG News Edition 12 Insights

Discover how ALLG’s impact was on show at EHA 2025 in Milan and the International Conference on Malignant Lymphoma in Switzerland, sharing key results from research in Acute Myeloid Leukaemia (AML), Lymphoma, and Chronic Myeloid Leukaemia (CML). Highlights included oral and poster presentations from our research leaders on our AMLM25 INTERVENE, NHL34 GOLDILOX, NHL39 POLAR BEAR and CML14 ASCENDANCE, HD10 and Supportive Care trials.

Our May 2025 Scientific Meeting in Sydney was another key recent event, bringing together researchers, clinicians, and partners to drive new research ideas forward. We were honoured to host keynote presentations from Professor Tony Lawler (Therapeutic Goods Administration) and international UK guest Dr Cathy Burton at our Meeting. We also recognised the contributions of our Early Career Clinician Researchers and newest ALLG Life Members. The event also celebrated our team’s achievements, including 10 years of service milestones and the ALLG Living Our Values Award.

This edition of ALLG News also shines a light on research into underrepresented diseases like Primary Central Nervous System (CNS) Lymphoma. The closure of recruitment for NHL32 BLOCK PCNSL, despite the rarity and complexity of the disease, marks a powerful achievement and reflects ALLG’s commitment to better treatments for rare blood cancer patient populations.

ALLG’s 2024 Research Report is now available and captures the full scope of our work over the past year. From advancing new treatments to strengthening international collaborations, it reflects the commitment to our mission to deliver Better treatments…Better lives for people affected by blood cancers.

Finally, we’re honoured to continue our partnership with The Dax Centre. The latest addition to the ALLG office features powerful artwork by Alison Ward, a Hodgkin’s Lymphoma survivor whose deeply personal pieces reflect her cancer journey through art. This moving collaboration reminds us of the human side of research – and why our work matters.

Download ALLG News Edition 12 to read more.

ALLG’s Impact – Advancing Blood Cancer Research

As Australasia’s only not-for-profit, collaborative clinical trials group dedicated solely to blood cancers, ALLG has been at the forefront of research for over 50 years. Our work continues to shape the way blood cancers are treated not just in Australia and New Zealand, but around the world. Over the past year alone, we’ve supported 1,061 patients and have an extensive portfolio of 75 + clinical trials.

Research is the driving force behind our progress. With a dedicated network of 1,500 clinicians and healthcare professionals, we’re driven by a shared goal – to accelerate discoveries that improve treatments, extend lives, and deliver real hope to people living with blood cancers.

Visit ALLG to learn more about our mission and discover how you can support our life-changing research.